# Journal of Medicinal Chemistry

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/journal-of-medicinal-chemistry/

## Facts

| Field | Value |
| --- | --- |
| Open Access | false |
| ISSN-L | 0022-2623 |
| ISSNs | 0022-2623,1520-4804 |
| OpenAlex ID | https://openalex.org/S162030435 |
| Publisher | American Chemical Society |

## Journal papers

Showing 12 of 68.

- [(2<i>R</i>)-4-Oxo-4-\[3-(Trifluoromethyl)-5,6-dihydro\[1,2,4\]triazolo\[4,3-<i>a</i>\]pyrazin- 7(8<i>H</i>)-yl\]-1-(2,4,5-trifluorophenyl)butan-2-amine:  A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes](https://scholariq.org/papers/2-i-r-i-4-oxo-4-3-trifluoromethyl-5-6-dihydro-1-2-4-triazolo-4-3-i-a-i-pyrazin-7/)
- [Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases](https://scholariq.org/papers/discovery-of-a-first-in-class-receptor-interacting-protein-1-rip1-kinase/)
- [Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-<i>N</i>2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-<i>N</i>4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials](https://scholariq.org/papers/synthesis-structure-activity-relationships-and-in-vivo-efficacy-of-the-novel/)
- [Discovery of Alogliptin:  A Potent, Selective, Bioavailable, and Efficacious Inhibitor of Dipeptidyl Peptidase IV](https://scholariq.org/papers/discovery-of-alogliptin-a-potent-selective-bioavailable-and-efficacious/)
- [Novel Inhibitors of DNA Gyrase:  3D Structure Based Biased Needle Screening, Hit Validation by Biophysical Methods, and 3D Guided Optimization. A Promising Alternative to Random Screening](https://scholariq.org/papers/novel-inhibitors-of-dna-gyrase-3d-structure-based-biased-needle-screening-hit/)
- [Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165](https://scholariq.org/papers/highly-selective-inhibition-of-tyrosine-kinase-2-tyk2-for-the-treatment-of/)
- [Discovery of 5-\[\[4-\[(2,3-Dimethyl-2<i>H</i>-indazol-6-yl)methylamino\]-2-pyrimidinyl\]amino\]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor](https://scholariq.org/papers/discovery-of-5-4-2-3-dimethyl-2-i-h-i-indazol-6-yl-methylamino-2-pyrimidinyl/)
- [Design, Synthesis, and Biological Evaluation of the First Selective Nonpeptide AT<sub>2</sub> Receptor Agonist](https://scholariq.org/papers/design-synthesis-and-biological-evaluation-of-the-first-selective-nonpeptide-at/)
- [Nonpeptide Angiotensin II Receptor Antagonists:  The Next Generation in Antihypertensive Therapy](https://scholariq.org/papers/nonpeptide-angiotensin-ii-receptor-antagonists-the-next-generation-in/)
- [Drug Discovery Targeting Bromodomain-Containing Protein 4](https://scholariq.org/papers/drug-discovery-targeting-bromodomain-containing-protein-4/)
- [Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor](https://scholariq.org/papers/allosteric-inhibition-of-shp2-identification-of-a-potent-selective-and-orally/)
- [DNA-Encoded Library Screening Identifies Benzo\[<i>b</i>\]\[1,4\]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors](https://scholariq.org/papers/dna-encoded-library-screening-identifies-benzo-i-b-i-1-4-oxazepin-4-ones-as/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.